Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study

Krupa Krishnaprasad*, Jane M. Andrews, Ian C. Lawrance, Timothy Florin, Richard B. Gearry, Rupert W L Leong, Gillian Mahy, Peter Bampton, Ruth Prosser, Peta Leach, Laurie Chitti, Charles Cock, Rachel Grafton, Anthony R. Croft, Sharon Cooke, James D. Doecke, Graham L. Radford-Smith

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Background: Crohn's disease (CD) exhibits significant clinical heterogeneity. Classification systems attempt to describe this; however, their utility and reliability depends on inter-observer agreement (IOA). We therefore sought to evaluate IOA using the Montreal Classification (MC). Methods: De-identified clinical records of 35 CD patients from 6 Australian IBD centres were presented to 13 expert practitioners from 8 Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC) centres. Practitioners classified the cases using MC and forwarded data for central blinded analysis. IOA on smoking and medications was also tested. Kappa statistics, with pre-specified outcomes of κ. >. 0.8 excellent; 0.61-0.8 good; 0.41-0.6 moderate and ≤. 0.4 poor, were used. Results: 97% of study cases had colonoscopy reports, however, only 31% had undergone a complete set of diagnostic investigations (colonoscopy, histology, SB imaging). At diagnosis, IOA was excellent for age, κ=0.84; good for disease location, κ=0.73; only moderate for upper GI disease (κ=0.57) and disease behaviour, κ=0.54; and good for the presence of perianal disease, κ=0.6. At last follow-up, IOA was good for location, κ=0.68; only moderate for upper GI disease (κ=0.43) and disease behaviour, κ=0.46; but excellent for the presence/absence of perianal disease, κ=0.88. IOA for immunosuppressant use ever and presence of stricture were both good (κ=0.79 and 0.64 respectively). Conclusion: IOA using MC is generally good; however some areas are less consistent than others. Omissions and inaccuracies reduce the value of clinical data when comparing cohorts across different centres, and may impair the ability to translate genetic discoveries into clinical practice.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalJournal of Crohn's and Colitis
Volume6
Issue number3
DOIs
Publication statusPublished - Apr 2012
Externally publishedYes

Keywords

  • Crohn's disease
  • Inter-observer agreement
  • Kappa statistics
  • Montreal Classification

Fingerprint Dive into the research topics of 'Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study'. Together they form a unique fingerprint.

Cite this